The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Alifirova V.M.

Siberian State Medical University

Kamenskikh E.M.

Siberian State Medical University

Koroleva E.S.

Siberian State Medical University

Kolokolova E.V.

Siberian State Medical University

Petrakovich A.M.

Siberian State Medical University

Prognostic markers of multiple sclerosis

Authors:

Alifirova V.M., Kamenskikh E.M., Koroleva E.S., Kolokolova E.V., Petrakovich A.M.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(2): 22‑27

DOI: 10.17116/jnevro202212202122

Read: 2908 times

Download PDF (RU)
Contact the author
Table of contents

PROGNOSTIC MARKERS OF MULTIPLE SCLEROSIS
PROGNOSTIC MARKERS OF MULTIPLE SCLEROSIS

To cite this article:

Alifirova VM, Kamenskikh EM, Koroleva ES, Kolokolova EV, Petrakovich AM. Prognostic markers of multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(2):22‑27. (In Russ.)
https://doi.org/10.17116/jnevro202212202122

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Multiple sclerosis (MS) is a chronic autoimmune disease with a high degree of heterogeneity due to course and prognosis. More than half of MS patients do not discuss their long-term prognosis with the doctor. At the same time, most patients consider the importance of personalized prognosis for decisions in family planning, career, and medical interventions. Clinical markers are used to determine the prognosis in routine clinical practice. However, it is nominally divided into positive and negative factors. It allows making a general conclusion about the MS prognosis. Neuroimaging and biological markers are used mostly for research purposes. But also they are already actively used in clinical trials for endpoint`s investigation. The review describes studies investigating prognostic clinical, neuroimaging, and biological markers.

Keywords:

prognosis
prognostic markers
multiple sclerosis
biomarkers
neuroimaging

Authors:

Alifirova V.M.

Siberian State Medical University

Kamenskikh E.M.

Siberian State Medical University

Koroleva E.S.

Siberian State Medical University

Kolokolova E.V.

Siberian State Medical University

Petrakovich A.M.

Siberian State Medical University

Received:

16.02.2021

Accepted:

04.03.2021

Close metadata

References:

  1. Vserossijskoe obshchestvo nevrologov. Klinicheskie rekomendacii «Rassennyj skleroz». 2019; Accessed February 15, 2021. (In Russ.). https://www.ructrims.org/files/%D0%9A%D0%BB%D0%B8%D0%BD%20%D1%80%D0%B5%D0%BA%D0%A0%D0%A1_2019_3.docx
  2. Ghasemi N, Razavi S, Nikzad E. Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy. Cell J. 2017;19(1):1-10.  https://doi.org/10.22074/cellj.2016.4867
  3. Wu Q, Mills EA, Wang Q, et al. AMS04 Study Group. Siponimod enriches regulatory T and B lymphocytes in secondary progressive multiple sclerosis. JCI Insight. 2020;5(3). https://doi.org/10.1172/jci.insight.134251
  4. Ziemssen T, Akgün K, Brück W. Molecular biomarkers in multiple sclerosis. J Neuroinflammation. 2019;16(1):272.  https://doi.org/10.1186/s12974-019-1674-2
  5. Bergamaschi R, Berzuini C, Romani A, Cosi V. Predicting secondary progression in relapsing — remitting multiple sclerosis: a Bayesian analysis. J Neurol Sci. 2001;189(1-2):13-21.  https://doi.org/10.1016/S0022-510X(01)00572-X
  6. Fambiatos A, Jokubaitis V, Horakova D, et al. Risk of secondary progressive multiple sclerosis: A longitudinal study. Mult Scler Houndmills Basingstoke Engl. 2020;26(1):79-90.  https://doi.org/10.1177/1352458519868990
  7. Briggs FBS, Yu JC, Davis MF, et al. Multiple sclerosis risk factors contribute to onset heterogeneity. Mult Scler Relat Disord. 2019;28:11-16.  https://doi.org/10.1016/j.msard.2018.12.007
  8. Boyko AN, Mugutdinova BT, Mugutdinov TM. Prognostic significance of neuropsychological tests in patients with typical remitting multiple sclerosis; Medicinskij Alfavit. 2018;2(17(354)); Accessed February 9, 2021. (In Russ.). https://elibrary.ru/item.asp?id=36574676
  9. Tilling K, Lawton M, Robertson N, et al. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort. Health Technol Assess Winch Engl. 2016;20(81):1-48.  https://doi.org/10.3310/hta20810
  10. Materialy 3-go Vserossijskogo kongressa s mezhdunarodnym uchastiem «Rasseyannyj skleroz i drugie demieliniziruyushchie zabolevaniya» (Kongress ROKIRS/RUCTRIMS, Ekaterinburg, 13—16 sentyabrya 2018 g.). Zjurnal Nevrologii i Psihiatrii im. S.S. Korsakova. Specvypuski. 2018;118(8-2):128-171. (In Russ.). https://doi.org/10.17116/jnevro2018118082128
  11. Volkov AI, Popova EV. Novye instrumenty dlya rannego vyyavleniya progressirovaniya rasseyannogo skleroza. Oprosnik MSProDiscuss [New tools for early detection of multiple sclerosis progression: MSProDiscuss questionnaire]. Zh Nevrol Psikhiatr im. S.S. Korsakova. 2020;120(7 Vyp. 2):43-47. (In Russ.). https://doi.org/10.17116/jnevro202012007243
  12. Jordy SS, Starzewski A Junior, Macedo FA, et al. Olfactory alterations in patients with multiple sclerosis. Arq Neuropsiquiatr. 2016;74(9):697-700.  https://doi.org/10.1590/0004-282X20160128
  13. Tonetti L, Camilli F, Giovagnoli S, Natale V, Lugaresi A. Circadian Activity Rhythm in Early Relapsing-Remitting Multiple Sclerosis. J Clin Med. 2019;8(12). https://doi.org/10.3390/jcm8122216
  14. Mirmosayyeb O, Brand S, Barzegar M, et al. Clinical Characteristics and Disability Progression of Early- and Late-Onset Multiple Sclerosis Compared to Adult-Onset Multiple Sclerosis. J Clin Med. 2020;9(5). https://doi.org/10.3390/jcm9051326
  15. Genovese AV, Hagemeier J, Bergsland N et al. Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis. Radiology. 2019;293(2):424-433.  https://doi.org/10.1148/radiol.2019190306
  16. Fisher E, Lee JC, Nakamura K, Rudick RA. Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol. 2008;64(3):255-265.  https://doi.org/10.1002/ana.21436
  17. Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain J Neurol. 2008;131(Pt 3):808-817.  https://doi.org/10.1093/brain/awm329
  18. Cortese R, Collorone S, Ciccarelli O, Toosy AT. Advances in brain imaging in multiple sclerosis. Ther Adv Neurol Disord. 2019;12.  https://doi.org/10.1177/1756286419859722
  19. Eshaghi A, Marinescu RV, Young AL, et al. Progression of regional grey matter atrophy in multiple sclerosis. Brain J Neurol. 2018;141(6):1665-1677. https://doi.org/10.1093/brain/awy088
  20. Eshaghi A, Prados F, Brownlee WJ, et al, MAGNIMS study group. Deep gray matter volume loss drives disability worsening in multiple sclerosis. Ann Neurol. 2018;83(2):210-222.  https://doi.org/10.1002/ana.25145
  21. Bross M, Hackett M, Bernitsas E. Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis. Int J Mol Sci. 2020;21(12):4312. https://doi.org/10.3390/ijms21124312
  22. Gajofatto A, Calabrese M, Benedetti MD, Monaco S. Clinical, MRI, and CSF Markers of Disability Progression in Multiple Sclerosis. Lichtinghagen R, ed. Dis Markers. 2013;35:484959. https://doi.org/10.1155/2013/484959
  23. Audoin B, Davies GR, Finisku L, Chard DT, Thompson AJ, Miller DH. Localization of grey matter atrophy in early RRMS. J Neurol. 2006;253(11):1495-1501. https://doi.org/10.1007/s00415-006-0264-2
  24. Rocca MA, Mesaros S, Pagani E, et al. Thalamic Damage and Long-term Progression of Disability in Multiple Sclerosis. Radiology. 2010;257(2):463-469.  https://doi.org/10.1148/radiol.10100326
  25. Preziosa P, Rocca MA, Mesaros S, et al. Intrinsic damage to the major white matter tracts in patients with different clinical phenotypes of multiple sclerosis: a voxelwise diffusion-tensor MR study. Radiology. 2011;260(2):541-550.  https://doi.org/10.1148/radiol.11110315
  26. Fox RJ, Cronin T, Lin J, et al. Measuring myelin repair and axonal loss with diffusion tensor imaging. AJNR Am J Neuroradiol. 2011;32(1):85-91.  https://doi.org/10.3174/ajnr.A2238
  27. Naismith RT, Xu J, Tutlam NT, et al. Increased diffusivity in acute multiple sclerosis lesions predicts risk of black hole. Neurology. 2010;74(21):1694-1701. https://doi.org/10.1212/WNL.0b013e3181e042c4
  28. Ontaneda D, Fox RJ. Imaging as an Outcome Measure in Multiple Sclerosis. Neurotherapeutics. 2017;14(1):24-34.  https://doi.org/10.1007/s13311-016-0479-6
  29. Absinta M, Sati P, Reich DS. Advanced MRI and staging of multiple sclerosis lesions. Nat Rev Neurol. 2016;12(6):358-368.  https://doi.org/10.1038/nrneurol.2016.59
  30. Dal-Bianco A, Grabner G, Kronnerwetter C et al. Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging. Acta Neuropathol (Berl). 2017;133(1):25-42.  https://doi.org/10.1007/s00401-016-1636-z
  31. Elliott C, Wolinsky JS, Hauser SL, et al. Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions. Mult Scler Houndmills Basingstoke Engl. 2019;25(14):1915-1925. https://doi.org/10.1177/1352458518814117
  32. Bogdan AA. Izmenenie funkcional’nogo sostoyaniya veshchestva golovnogo mozga pri rasseyannom skleroze po dannym protonnoj magnitno-rezonansnoj spektroskopii. Published online 2020. Accessed January 18, 2021. https://cutt.ly/cjFwnIN
  33. Golovkin VI, Pozdnyakov AV, Kamynin YuF, Martens I.S. New therapy prediction technologies in multiple sclerosis. Bulletin of Siberian Medicine. 2010;9(4):138-144. (In Russ.). https://doi.org/10.20538/1682-0363-2010-4-138-144
  34. Srinivasan R, Sailasuta N, Hurd R, Nelson S, Pelletier D. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain J Neurol. 2005;128(Pt 5):1016-1025. https://doi.org/10.1093/brain/awh467
  35. Kobys TA. Neuroimaging predictors of disability progression in multiple sclerosis. The Bulletin of Contemporary Clinical Medicine. 2016;9(4):7-14. (In Russ.). https://cyberleninka.ru/article/n/neyrovizualizatsionnye-prediktory-progressirovaniya-invalidizatsii-pri-rasseyannom-skleroze
  36. Tur C, Eshaghi A, Altmann DR, et al. Structural cortical network reorganization associated with early conversion to multiple sclerosis. Sci Rep. 2018;8(1):10715. https://doi.org/10.1038/s41598-018-29017-1
  37. Charalambous T, Tur C, Prados F, et al. Structural network disruption markers explain disability in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2019;90(2):219-226.  https://doi.org/10.1136/jnnp-2018-318440
  38. Nourbakhsh B, Mowry E M. Multiple Sclerosis Risk Factors and Pathogenesis. Contin Minneap Minn. 2019;25(3):596-610.  https://doi.org/10.1212/CON.0000000000000725
  39. Teunissen ChE, Tumani H, Engelborghs S, Mollenhauer B. Biobanking of CSF: international standardization to optimize biomarker development. Clin Biochem. 2014;47(4-5):288-292.  https://doi.org/10.1016/j.clinbiochem.2013.12.024
  40. Tintore M, Rovira À, Río J, et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain J Neurol. 2015;138(Pt 7):1863-1874. https://doi.org/10.1093/brain/awv105
  41. Kuhle J, Disanto G, Dobson R, et al. Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Mult Scler Houndmills Basingstoke Engl. 2015;21(8):1013-1024. https://doi.org/10.1177/1352458514568827
  42. Hinsinger G, Galéotti N, Nabholz N, et al. Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis. Mult Scler Houndmills Basingstoke Engl. 2015;21(10):1251-1261. https://doi.org/10.1177/1352458514561906
  43. Boesen MS, Jensen PEH, Magyari M, et al. Increased cerebrospinal fluid chitinase 3-like 1 and neurofilament light chain in pediatric acquired demyelinating syndromes. Mult Scler Relat Disord. 2018;24:175-183.  https://doi.org/10.1016/j.msard.2018.05.017
  44. Thouvenot E, Hinsinger G, Demattei Ch, et al. Cerebrospinal fluid chitinase-3-like protein 1 level is not an independent predictive factor for the risk of clinical conversion in radiologically isolated syndrome. Mult Scler Houndmills Basingstoke Engl. 2019;25(5):669-677.  https://doi.org/10.1177/1352458518767043
  45. Kušnierová P, Zeman D, Hradílek P, et al. Determination of chitinase 3-like 1 in cerebrospinal fluid in multiple sclerosis and other neurological diseases. PLOS ONE. 2020;15(5):e0233519. https://doi.org/10.1371/journal.pone.0233519
  46. Modvig S, Degn M, Roed H, et al. Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis. Mult Scler Houndmills Basingstoke Engl. 2015;21(14):1761-1770. https://doi.org/10.1177/1352458515574148
  47. Baldacci F, Lista S, Palermo G, et al. The neuroinflammatory biomarker YKL-40 for neurodegenerative diseases: advances in development. Expert Rev Proteomics. 2019;16(7):593-600.  https://doi.org/10.1080/14789450.2019.1628643
  48. Khalil M, Salzer J. CSF neurofilament light. Neurology. 2016;87(11):1068. https://doi.org/10.1212/WNL.0000000000003107
  49. Dong DL, Xu ZS, Chevrier MR, et al. Glycosylation of mammalian neurofilaments. Localization of multiple O-linked N-acetylglucosamine moieties on neurofilament polypeptides L and M. J Biol Chem. 1993;268(22):16679-16687.
  50. Khalil M, Teunissen ChE, Otto M, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14(10):577-589.  https://doi.org/10.1038/s41582-018-0058-z
  51. Barro Ch, Benkert P, Disanto G, et al. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain. 2018;141(8):2382-2391. https://doi.org/10.1093/brain/awy154
  52. Ciccarelli O. Multiple sclerosis in 2018: new therapies and biomarkers. Lancet Neurol. 2019;18(1):10-12.  https://doi.org/10.1016/S1474-4422(18)30455-1
  53. Kuhle J, Disanto G, Lorscheider J, et al. Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Neurology. 2015;84(16):1639-1643. https://doi.org/10.1212/WNL.0000000000001491
  54. Gaetani L, Boscaro F, Pieraccini G, et al. Host and Microbial Tryptophan Metabolic Profiling in Multiple Sclerosis. Front Immunol. 2020;11.  https://doi.org/10.3389/fimmu.2020.00157
  55. Lim Ch K, Bilgin A, Lovejoy D B, et al. Kynurenine pathway metabolomics predicts and provides mechanistic insight into multiple sclerosis progression. Sci Rep. 2017;7:41473. https://doi.org/10.1038/srep41473
  56. Ak P, Se B. The Role of the Gut Microbiome in Multiple Sclerosis Risk and Progression: Towards Characterization of the «MS Microbiome». Neurother J Am Soc Exp Neurother. 2018;15.  https://doi.org/10.1007/s13311-017-0587-y
  57. Dennison L, Brown M, Kirby S, Galea I. Do people with multiple sclerosis want to know their prognosis? A UK nationwide study. PLoS ONE. 2018;13(2). https://doi.org/10.1371/journal.pone.0193407
  58. Magliozzi R, Howell O W, Nicholas R, et al. Inflammatory intrathecal profiles and cortical damage in multiple sclerosis. Ann Neurol. 2018;83(4):739-755.  https://doi.org/https://doi.org/10.1002/ana.25197
  59. Häring DA, Kropshofer H, Kappos L, et al. Long-term prognostic value of longitudinal measurements of blood neurofilament levels. Neurol — Neuroimmunol Neuroinflammation. 2020;7(5):e856. https://doi.org/10.1212/NXI.0000000000000856
  60. Challenges in design, analysis and reporting of prognostic and predictive marker research — from single studies to an EBM based assessment. Accessed March 3, 2021. https://methods.cochrane.org/sites/methods.cochrane.org.prognosis/files/public/uploads/program+abstracts.pdf
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.